Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2011, Article ID 381203, 8 pages
http://dx.doi.org/10.1155/2011/381203
Case Report

Octreotide-Treated Diabetes Accompanied by Endogenous Hyperinsulinemic Hypoglycemia and Protein-Losing Gastroenteropathy

1Department of Internal Medicine, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Toubetsu, Hokkaido 061-0293, Japan
2Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan
3Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan

Received 14 February 2011; Revised 11 May 2011; Accepted 14 June 2011

Academic Editor: S. A. Sahn

Copyright © 2011 Nobuhiko Takahashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. J. Service, “Hypoglycemic disorders,” New England Journal of Medicine, vol. 332, no. 17, pp. 1144–1152, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. G. F. Laidlaw, “Nesidioblastoma, the islet tumor of the pancreas,” American Journal of Pathology, vol. 14, no. 2, pp. 125–134, 1938. View at Google Scholar
  3. M. F. Carroll, M. R. Burge, and D. S. Schade, “Severe hypoglycemia in adults,” Reviews in Endocrine and Metabolic Disorders, vol. 4, no. 2, pp. 149–157, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Klöppel, M. Anlauf, A. Raffel, A. Perren, and W. T. Knoefel, “Adult diffuse nesidioblastosis: genetically or environmentally induced?” Human Pathology, vol. 39, no. 1, pp. 3–8, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. R. Sandler, D. L. Horwitz, A. H. Rubenstein, and H. Kuzuya, “Hypoglycemia and endogenous hyperinsulinism complicating diabetes mellitus. Application of the C peptide assay to diagnosis and therapy,” American Journal of Medicine, vol. 59, no. 5, pp. 730–736, 1975. View at Google Scholar · View at Scopus
  6. D. Vezzosi, A. Bennet, J. Fauvel, and P. Caron, “Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism,” European Journal of Endocrinology, vol. 157, no. 1, pp. 75–83, 2007. View at Publisher · View at Google Scholar · View at PubMed
  7. M. Imamura, Y. Shimada, M. Kato, R. Doi, N. Okada, and M. Hashimoto, “Usefulness of selective arterial calcium injection test and secretin test in patients with insulinoma,” Journal of Hepato-Biliary-Pancreatic Surgery, vol. 1, no. 5, pp. 530–534, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. J. L. Doppman, R. Chang, D. L. Fraker et al., “Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium,” Annals of Internal Medicine, vol. 123, no. 4, pp. 269–273, 1995. View at Google Scholar · View at Scopus
  9. D. Vezzosi, A. Bennet, F. Courbon, and P. Caron, “Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism,” Clinical Endocrinology, vol. 68, no. 6, pp. 904–911, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. A. B. Ballinger and M. J. G. Farthing, “Octreotide in the treatment of intestinal lymphangiectasia,” European Journal of Gastroenterology and Hepatology, vol. 10, no. 8, pp. 699–702, 1998. View at Google Scholar · View at Scopus
  11. J. M. Guettier, A. Kam, R. Chang et al., “Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 4, pp. 1074–1080, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. C. K. Brown, D. L. Bartlett, J. L. Doppman et al., “Intraarterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas,” Surgery, vol. 122, no. 6, pp. 1189–1194, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Y. Lo, F. L. Chan, S. C. F. Tam et al., “Value of intra-arterial calcium stimulated venous sampling for regionalization of pancreatic insulinomas,” Surgery, vol. 128, no. 6, pp. 903–909, 2000. View at Google Scholar · View at Scopus
  14. K. Ibukuro, “Vascular anatomy of the pancreas and clinical applications,” International Journal of Gastrointestinal Cancer, vol. 30, no. 1-2, pp. 87–104, 2001. View at Google Scholar · View at Scopus
  15. Y. Hayashi, H. Masuda, T. Eizawa, T. Yamanaka, and M. Naka, “Usefulness of the combination of pre- and intraoperative selective intraarterial calcium injection to detect residual insulinomas,” Internal Medicine, vol. 40, no. 1, pp. 48–51, 2001. View at Google Scholar · View at Scopus
  16. L. Defreyne, K. König, M. M. Lerch et al., “Modified intra-arterial calcium stimulation with venous sampling test for preoperative localization of insulinomas,” Abdominal Imaging, vol. 23, no. 3, pp. 322–331, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Tsagarakis, J. Kaskarelis, C. Malagari et al., “Regionalization of occult pancreatic insulinomas with the arterial stimulation venous sampling (ASVS) technique,” Clinical Endocrinology, vol. 47, no. 6, pp. 753–757, 1997. View at Google Scholar · View at Scopus
  18. D. O'Shea, A. W. Rohrer-Theus, J. A. Lynn, J. E. Jackson, and S. R. Bloom, “Localization of insulinomas by selective intraarterial calcium injection,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 4, pp. 1623–1627, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. C. J. Filipi and G. A. Higgins, “Diagnosis and management of insulinoma,” The American Journal of Surgery, vol. 125, no. 2, pp. 231–239, 1973. View at Google Scholar · View at Scopus
  20. J. M. Howard, N. H. Moss, and J. E. Rhoads, “Hyperinsulinism and islet cell tumors of the pancreas; with 398 recorded tumors,” International abstracts of surgery, vol. 90, no. 5, pp. 417–455, 1950. View at Google Scholar · View at Scopus
  21. Y. C. Kon, K. C. Loh, S. P. Chew et al., “Hypoglycaemia from islet cell hyperplasia and nesidioblastosis in a patient with type 2 diabetes mellitus—a case report,” Annals of the Academy of Medicine Singapore, vol. 29, no. 5, pp. 682–687, 2000. View at Google Scholar · View at Scopus
  22. K. M. Rice, M. A. Turnbow, and C. W. Garner, “Insulin stimulates the degradation of IRS-1 in 3T3-L1 adipocytes,” Biochemical and Biophysical Research Communications, vol. 190, no. 3, pp. 961–967, 1993. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. J. Škrha, G. Šindelka, T. Haas, J. Hilgertová, and V. Justová, “Comparison of insulin sensitivity in patients with insulinoma and obese type 2 diabetes mellitus,” Hormone and Metabolic Research, vol. 28, no. 11, pp. 595–598, 1996. View at Google Scholar
  24. D. J. Drucker, “The role of gut hormones in glucose homeostasis,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 24–32, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. T. Vilsbøll, T. Krarup, J. Sonne et al., “Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2706–2713, 2003. View at Google Scholar · View at Scopus
  26. K. Vollmer, J. J. Hoist, B. Bailer et al., “Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance,” Diabetes, vol. 57, no. 3, pp. 678–687, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. J. Miholic, C. Orskov, J. J. Holst, J. Kotzerke, and H. J. Meyer, “Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy,” Digestive Diseases and Sciences, vol. 36, no. 10, pp. 1361–1370, 1991. View at Google Scholar · View at Scopus
  28. A. B. Goldfine, E. C. Mun, E. Devine et al., “Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 12, pp. 4678–4685, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. D. Yabe, A. Kuroe, S. Lee et al., “Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls,” Journal of Diabetes Investigation, vol. 1, no. 1-2, pp. 56–59, 2010. View at Publisher · View at Google Scholar
  30. P. N. Goode, J. R. Farndon, and J. Anderson, “Diazoxide in the management of patients with insulinoma,” World Journal of Surgery, vol. 10, no. 4, pp. 586–592, 1986. View at Google Scholar · View at Scopus
  31. M. Dabrowski, T. Larsen, F. M. Ashcroft, J. Bondo Hansen, and P. Wahl, “Potent and selective activation of the pancreatic beta-cell type K ATP channel by two novel diazoxide analogues,” Diabetologia, vol. 46, no. 10, pp. 1375–1382, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. C. J. Fasano, G. O'Malley, P. Dominici, E. Aguilera, and D. R. Latta, “Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia,” Annals of Emergency Medicine, vol. 51, no. 4, pp. 400–406, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. R. Candrina and G. Giustina, “Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients,” Journal of Endocrinological Investigation, vol. 11, no. 7, pp. 501–507, 1988. View at Google Scholar · View at Scopus
  34. J. E. Gerich, T. A. Schultz, S. B. Lewis, and J. H. Karam, “Clinical evaluation of somatostatin as a potential adjunct to insulin in the management of diabetes mellitus,” Diabetologia, vol. 13, no. 5, pp. 537–544, 1977. View at Google Scholar · View at Scopus
  35. M. E. Kraenzlin, J. L. C. Ch'ng, and S. M. Wood, “Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases,” Gastroenterology, vol. 88, no. 1, pp. 185–187, 1985. View at Google Scholar · View at Scopus
  36. L. K. Kvols, C. G. Moertel, and M. J. O'Connell, “Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue,” New England Journal of Medicine, vol. 315, no. 11, pp. 663–666, 1986. View at Google Scholar · View at Scopus
  37. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, “Report of the Committee on the classification and diagnostic criteria of diabetes mellitus,” Diabetology International, vol. 1, no. 1, pp. 2–20, 2010. View at Google Scholar